<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>AFP &#8211; mikrobik.net</title>
	<atom:link href="https://wp.mikrobik.net/tag/afp/feed/" rel="self" type="application/rss+xml" />
	<link>https://wp.mikrobik.net</link>
	<description></description>
	<lastBuildDate>Wed, 25 Jun 2025 20:40:28 +0000</lastBuildDate>
	<language>tr</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>
	<item>
		<title>Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma</title>
		<link>https://wp.mikrobik.net/golgi-protein-73-versus-alpha-fetoprotein-as-a-biomarker-for-hepatocellular-carcinoma/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 21 May 2012 15:46:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[AFP]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Zhou Y, Yin X, Ying J, Zhang B. BMC Cancer. 2012 Jan 16;12:17. Abstract BACKGROUNDS: There have been conflicting...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#204A87;">Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis</span>.</strong><br />
Zhou Y, Yin X, Ying J, Zhang B.</p>
<p><a href="http://www.biomedcentral.com/content/pdf/1471-2407-12-17.pdf" target="_blank" rel="noopener">BMC Cancer. 2012 Jan 16;12:17.</a></p>
<p>Abstract<br />
BACKGROUNDS:</p>
<p>There have been conflicting reports about serum golgi protein 73 (GP73) as one of the most promising serum markers for the diagnosis of hepatocellular carcinoma (HCC). This study was to make a systematic review about the diagnostic accuracy of serum GP73 versus alpha-fetoprotein (AFP) for HCC.<br />
METHODS:</p>
<p>After a systematic review of related studies, sensitivity, specificity and other measures about the accuracy of serum GP73 and AFP in the diagnosis of HCC were pooled using random-effects models. Summary receiver operating characteristic curve analysis was used to summarize the overall test performance.<br />
RESULTS:</p>
<p>Eight studies were included in our meta-analysis. The summary estimates for serum GP73 and AFP in diagnosing HCC in the studies included were as follows: sensitivity, 76% (95% confidence interval (CI) 51-91%) vs. 70% (47-86%); specificity, 86% (95%CI 65-95%) vs. 89% (69-96%); diagnostic odds ratio (DOR), 18.59 (95%CI 5.33-64.91) vs. 18.00(9.41-34.46); and area under sROC, 0.88 (95%CI 0.77-0.99) vs. 0.86 (95%CI 0.84-0.87).<br />
CONCLUSIONS:</p>
<p>The current evidence indicates that serum GP73 has a comparable accuracy to AFP for the diagnosis of HCC, while the value of serum GP73 in combination with AFP for HCC detection deserves further investigation.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications</title>
		<link>https://wp.mikrobik.net/diagnosing-and-monitoring-hepatocellular-carcinoma-with-alpha-fetoprotein-new-aspects-and-applications/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Thu, 12 Mar 2009 13:12:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[AFP]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications Evi N. Debruyne and Joris R. Delanghe Clinica Chimica Acta 395 (2008) 19–26 Hepatocellular carcinoma is the 5th most common cancer in...]]></description>
										<content:encoded><![CDATA[<p><strong>Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications</strong><br />
Evi N. Debruyne and Joris R. Delanghe</p>
<p><a href="http://www.sciencedirect.com/science?_ob=MImg&#038;_imagekey=B6T57-4SHVSYH-1-1&#038;_cdi=4995&#038;_user=1010270&#038;_orig=search&#038;_coverDate=09%2F30%2F2008&#038;_sk=996049998&#038;view=c&#038;wchp=dGLzVtb-zSkzS&#038;md5=77de5e1c109838858cc40b2b5c4eccd0&#038;ie=/sdarticle.pdf" target="_blank" rel="noopener">Clinica Chimica Acta 395 (2008) 19–26</a></p>
<p>Hepatocellular carcinoma is the 5th most common cancer in the world. Prognosis for this disease is poor since hepatocellular carcinoma is mostly diagnosed at an advanced stage. Serum alpha-fetoprotein (AFP) is one of the most common diagnostic markers for hepatocellular carcinoma. However, its diagnostic value is more and more questioned. Therefore, research has focussed on AFP related parameters (AFP mRNA and AFP glycoforms). The aim of this paper is to review the present knowledge on AFP and its related parameters in diagnosing and monitoring HCC. AFP related parameters can be arranged in two types: AFP mRNA and AFP glycoforms. AFP mRNA is a potentially prognostic marker and AFP mRNA assays are based on PCR techniques. The AFP glycoforms have diagnostic potential and assays are based on isoelectric focussing and lectin affinity electrophoretic methods. Up to now the diagnostic use of the AFP related parameters is limited. Although some of them are recommended as a complementary test, they cannot (yet) replace serum AFP as the golden standard of diagnostic markers for hepatocellular carcinoma.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
